Overt hypothyroidism is associated with accelerated atherosclerosis and an increased risk of coronary artery disease (CAD).[@b1]--[@b3] While some of these effects can be explained by a higher prevalence of hypertension and dyslipidemia in patients with hypothyroidism,[@b4]--[@b7] not all individuals with hypothyroidism have abnormal blood pressure or lipid profiles.[@b8] In addition, studies have shown an increased risk of all-cause mortality[@b9] and cardiovascular events[@b10] in patients with hypothyroidism, even after adjusting for the presence of conventional cardiovascular risk factors, implicating other factors in their elevated risk.

Endothelial dysfunction is characterized by an imbalance between vasodilator and vasoconstrictor activity in response to endothelial-dependent vasodilating agents such as acetylcholine.[@b11]--[@b14] Coronary endothelial dysfunction may affect microvascular or epicardial vessels: Microvascular endothelial dysfunction can be identified as an attenuated increase or a decrease in coronary blood flow (CBF)[@b15]--[@b19] while epicardial endothelial dysfunction can be identified as coronary artery vasoconstriction[@b13],[@b18],[@b20],[@b21] in response to intracoronary infusions of acetylcholine. Endothelial dysfunction has been shown to represent an early stage of atherosclerosis[@b22],[@b23] and is associated with coronary plaque progression[@b24] and the presence of necrotic plaque,[@b25] which is particularly vulnerable to rupture. Endothelial dysfunction is also independently associated with an increased risk of adverse cardiovascular events.[@b26],[@b27] Moreover, endothelial dysfunction has been associated with local macrophages and microchannels in early atherosclerosis[@b28] as well as elevated local coronary[@b29] and systemic[@b30] levels of lipoprotein-associated phospholipase A2, features consistent with inflammation. As hypothyroidism is also believed to arise from inflammatory processes,[@b31] concomitant coronary endothelial dysfunction could account for some of the increased risk observed in hypothyroid patients.

Previous studies that evaluated the prevalence of endothelial dysfunction in patients with hypothyroidism have been limited by a small sample size[@b32]--[@b38] and the use of noninvasive techniques to assess endothelial dysfunction in the brachial artery[@b32],[@b33],[@b35]--[@b40] or in the left anterior descending coronary artery,[@b34] which are less direct than invasive methods. The aim of this study was to determine whether microvascular and epicardial endothelial dysfunction identified invasively are associated with hypothyroidism in a large cohort of patients presenting with nonobstructive CAD.

Methods
=======

The following protocol was approved by the Mayo Clinic Institutional Review Board, and all patients provided written informed consent. Patients presenting with chest pain were referred by their physicians for diagnostic coronary angiography. Invasive endothelial functional testing was then undertaken in all patients with the exception of those with obstructive CAD (\>40% diameter stenosis of any coronary artery determined at angiography); uncontrolled hypertension; left ventricular ejection fraction \<50% or left ventricular hypertrophy determined on echocardiography or acute coronary syndrome.[@b21],[@b41]

Assessment of Coronary Endothelial Function
-------------------------------------------

Consecutive patients presented to the cardiac catheterization laboratory in the fasting state and all cardiovascular medications, including nitrates and calcium channel blockers, had been discontinued for at least 48 hours. Routine diagnostic coronary angiography was performed on all patients using standard clinical protocols. Angiograms were reviewed prior to the infusion of any pharmacological agent. In cases where the severity of stenosis was uncertain, online quantitative coronary angiography was used. Patients then underwent evaluation of coronary endothelial-dependent epicardial and microvascular function as previously described.[@b18],[@b20],[@b21],[@b41] In brief, following intravenous administration of 5000 to 7000 U of heparin, a Doppler guidewire (FloWire, Volcano Inc) 0.014 inches in diameter within a 3-F Slip-Cath Infusion Catheter (Cook Medical) was positioned into the midportion of the left anterior descending coronary artery, 2 to 3 mm distal to the tip of the infusion catheter. Acetylcholine was infused into the left anterior descending coronary artery at concentrations of 10^−6^, 10^−5^, and 10^−4^ mol/L (to achieve estimated coronary bed concentrations of 10^−8^, 10^−7^, and 10^−6^ mol/L, respectively) for 3 minutes at each concentration to assess coronary endothelial function.[@b18],[@b20],[@b21],[@b41] Infusions were performed using a Harvard pump to maintain infusion rates of \<1% of the estimated CBF. Doppler measurements of mean peak velocity were performed after each infusion followed by repeat coronary angiography. Coronary artery diameter was measured at baseline and after the infusion with acetylcholine by an independent investigator blinded to Doppler velocity data using a previously described computer-based image analysis system.[@b42],[@b43] The percentage change in coronary artery diameter in response to intracoronary acetylcholine compared to baseline (% Δ CAD Ach) was then calculated as an index of epicardial endothelial function. CBF was also calculated using the following, as previously described[@b18],[@b20]: CBF=π (mean peak velocity/2)(coronary artery diameter/2)^2^. The average maximal percentage increase in CBF in response to acetylcholine compared to CBF at baseline (% Δ CBF Ach) was calculated as an index of microvascular endothelial function. For quality control, all measurements were performed in the segment 5 mm distal to the tip of the Doppler guidewire and following each infusion, the diameter was measured in the same segment of the vessel.[@b18],[@b20],[@b21],[@b41]

Hypothyroidism Status
---------------------

Patients who had undergone endothelial functional assessment were retrospectively divided into 2 groups: hypothyroidism, defined as a history of hypothyroidism documented in the patient's medical record or a thyroid-stimulating hormone (TSH) \>10.0 mU/mL within 1 month of the patient's endothelial functional assessment, and euthyroidism, defined as 0.3\<TSH≤10.0 mU/mL within 1 month of the index procedure and/or no documented history of hypothyroidism in the medical record. Patients with a TSH \<0.3 mU/mL or a documented history of hyperthyroidism were excluded from all analyses. All medical records were reviewed by a single investigator (J.S.) blinded to endothelial function data. After initial screening of medical records, patients categorized as hypothyroid had their clinical record reviewed again by a Consultant Endocrinologist (H.G.) to confirm the history of hypothyroidism, and in cases of discrepancy, the Consultant's decision was accepted.

Patients in the hypothyroidism group had their medical record evaluated further to determine whether they were prescribed thyroid replacement therapy (TRT) at the time of the procedure. As part of a subanalysis, patients from the hypothyroidism group who took TRT and had a TSH level documented within 1 month of the index procedure were divided according to whether they had adequate replacement on TRT, defined as 0.3 mU/mL\<TSH≤10.0 mU/mL versus inadequate replacement on TRT, defined as TSH \>10.0 mU/mL.[@b44]

In a separate final analysis, only patients with a TSH documented within 1 month of the index procedure were included, and patients were divided according to their TSH value only, regardless of past medical history, as follows: euthyroidism, 0.3 mU/mL\<TSH≤4.5 mU/mL; subclinical hypothyroidism (SCH), 4.5 mU/mL\<TSH≤10.0 mU/mL; and hypothyroidism, TSH \>10.0 mU/mL.[@b44]

Other Patient Information
-------------------------

Data were collected on conventional cardiovascular risk factors including age, sex, hypertension, diabetes mellitus, hyperlipidemia, smoking, and body mass index (BMI). Hypertension was defined as a history of hypertension treated with antihypertensives; diabetes was defined as a history of diabetes treated with medication or insulin; and hyperlipidemia was defined as a history of total cholesterol levels of \>240 mg/dL or treatment with lipid-lowering therapy. Information was also collected on a previous history of myocardial infarction (defined as a history of previous myocardial infarction documented in the patients' clinical record or on patient self-report); other vasospasm disorders (defined as a history of Raynaud's phenomenon or migraine headaches documented in the patients' clinical record or on self-report); and other vascular diseases (defined as a history of peripheral vascular disease, stroke, or transient ischemic attack documented in the patient's clinical record or on self -report). Blood samples for routine clinical laboratory tests (complete blood count, glucose, creatinine, and lipid profile) were drawn in all patients in the fasting state 48 hours before the procedure.

Statistical Analysis
--------------------

Continuous variables are presented as a mean (SD) where data are normally distributed and as a median (quartile 1, quartile 3) for skewed data. Categorical variables are presented as frequencies (percentages). Differences between groups were analyzed using Student *t* test, Wilcoxon rank sign test, or Kruskal--Wallis test as appropriate for continuous variables. Correlation was assessed using Spearman's correlation coefficient. Linear regression models were analyzed to estimate the partial association between hypothyroidism and adequate replacement on TRT with % Δ CAD Ach and % Δ CBF Ach. Risk factors from [Table 1](#tbl1){ref-type="table"} known to be associated with hypothyroidism and coronary endothelial dysfunction were included, and no risk factor considered for the model had \>10% missing data. *P*-values of \<0.05 were accepted as significant. All statistical analyses were performed using JMP 9 software (SAS Institute, Inc, Cary, NC).

###### 

Summary of Baseline Characteristics for Patients With Hypothyroidism and Euthyroidism

  Clinical Variable                                       Hypothyroid, N=188   Euthyroid, N=1200   *P* Value
  ------------------------------------------------------- -------------------- ------------------- ------------------------------------------
  Age, y (SD)                                             55.73 (11.25)        49.64 (12.29)       \<0.001[\*](#tf1-2){ref-type="table-fn"}
  Female, n (%)                                           166 (88.30)          742 (61.94)         \<0.001[\*](#tf1-2){ref-type="table-fn"}
  BMI, kg/m^2^ (SD)                                       30.15 (6.17)         28.74 (6.17)        0.004[\*](#tf1-2){ref-type="table-fn"}
  Hypertension, n (%)                                     89 (47.59)           513 (42.82)         0.42
  Diabetes mellitus, n (%)                                28 (14.89)           98 (8.16)           0.007[\*](#tf1-2){ref-type="table-fn"}
  Hyperlipidemia, n (%)                                   116 (61.70)          646 (53.88)         0.13
  History of MI, n (%)                                    32 (17.02)           177 (14.76)         0.69
  History of vascular disease, n (%)                      17 (9.04)            87 (7.25)           0.01[\*](#tf1-2){ref-type="table-fn"}
  Smoking status, n (%)                                                                            0.13
   Never smoked                                           104 (55.32)          605 (50.37)         
   Former smoker                                          70 (37.23)           433 (36.05)         
   Current smoker                                         13 (6.91)            152 (12.66)         
  Total cholesterol, mg/dL (SD)                           195.24 (52.03)       185.66 (42.27)      0.02[\*](#tf1-2){ref-type="table-fn"}
  HDL-C, mg/dL (SD)                                       57.55 (18.56)        53.11 (17.23)       0.003[\*](#tf1-2){ref-type="table-fn"}
  LDL-C, mg/dL (SD)                                       107.91 (42.06)       105.99 (36.27)      0.57
  Triglycerides, mg/dL (SD)                               142.44 (88.40)       132.51 (92.07)      0.17
  Creatinine, mg/dL (SD)                                  0.99 (0.44)          0.99 (0.68)         0.99
  Glucose, mg/dL (SD)                                     101.04 (24.51)       99.76 (25.29)       0.52
  Aspirin, n (%)                                          95 (50.53)           578 (48.17)         0.55
  ACE inhibitor, n (%)                                    29 (15.43)           171 (14.25)         0.67
  β-Blocker, n (%)                                        63 (33.51)           335 (27.92)         0.11
  Calcium channel blocker, n (%)                          58 (31.02)           418 (34.83)         0.50
  Lipid-lowering therapy, n (%)                           83 (44.15)           422 (35.17)         0.02[\*](#tf1-2){ref-type="table-fn"}
  Nitrates, n (%)                                         65 (34.57)           431 (35.92)         0.72
  Thyroid replacement therapy, n (%)                      184 (97.87)          0 (0.00)            \<0.001[\*](#tf1-2){ref-type="table-fn"}
  Estrogen replacement therapy (in females only), n (%)   54 (32.53)           164 (22.10)         \<0.001[\*](#tf1-2){ref-type="table-fn"}
  Corticosteroids, n (%)                                  21 (11.17)           81 (6.75)           0.09

ACE indicates angiotensin-converting enzyme; BMI, body mass index; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction.

Corresponds to *P*\<0.05.

Results
=======

Between January 1, 1993 and December 31, 2012, a total of 1591 endothelial functional assessment procedures were performed on 1552 consecutive unique patients. Of these, 1498 granted use of their records for research purposes in keeping with Minnesota statute. For each patient, only the first study date available was examined. Of these, 1439 had measurements available for both % Δ CBF Ach and % Δ CAD Ach. Thirty-six patients were excluded due to insufficient documentation in their medical record, and 15 were excluded due to a past medical history of hyperthyroidism or a TSH \<0.3 mU/mL within 1 month of the index procedure, leaving 1388 patients in this study ([Figure 1](#fig01){ref-type="fig"}).

![Flow diagram demonstrating patient enrollment and study protocol. TRT indicates thyroid replacement therapy; TSH, thyroid-stimulating hormone.](jah30004-e002225-f1){#fig01}

Baseline Characteristics
------------------------

One hundred eighty-eight (13.5%) patients had a history of hypothyroidism or a TSH \>10.0 mU/mL, and 1200 were euthyroid. [Table 1](#tbl1){ref-type="table"} summarizes their baseline characteristics. The hypothyroid group was significantly older; had a higher proportion of females; a higher BMI; a higher proportion of diabetics; and a higher frequency of a history of vascular disease compared with the euthyroid group. Other risk factors were not significantly different between groups. Patients with hypothyroidism also had a significantly higher total cholesterol and higher high-density lipoprotein-cholesterol (HDL) compared to the euthyroid group, while other blood laboratory results did not vary significantly between groups. A greater proportion of the hypothyroid group took lipid-lowering therapy and among females, a higher proportion of the hypothyroid group took estrogen replacement therapy compared to the euthyroid group. One hundred eighty-four patients (98%) of the hypothyroid group took TRT.

Clinical History of Hypothyroidism and Coronary Endothelial Function
--------------------------------------------------------------------

Among all patients, the hypothyroid group had a significantly lower % Δ CBF Ach (mean \[SD\] %: 48.26 \[80.66\] versus 64.58 \[128.30\], *P*\<0.05) compared to the euthyroid group ([Figure 2A](#fig02){ref-type="fig"}) while the % Δ CAD Ach did not vary significantly between groups (mean \[SD\] %: −11.91 \[19.92\] versus −13.94 \[22.46\], *P*=0.20) ([Figure 2B](#fig02){ref-type="fig"}). However, in a multivariate analysis adjusting for diabetes, hypertension, age, BMI, and total and HDL cholesterol, hypothyroidism was not significantly associated with the % Δ CBF Ach or % Δ CAD Ach in all patients ([Figure 3A](#fig03){ref-type="fig"} and [3B](#fig03){ref-type="fig"}).

![A, Average maximum percentage change in coronary blood flow in response to acetylcholine between hypothyroid and euthyroid patients. \*Signifies *P*\<0.05; T-bars represent standard errors. The percentage change in coronary blood flow in response to acetylcholine, as a metric of microvascular endothelial function, was significantly lower in patients with hypothyroidism compared to euthyroidism among all patients and females. B, Average maximum percentage change in coronary artery diameter in response to acetylcholine between hypothyroid and euthyroid patients. \*Signifies *P*\<0.05; T-bars represent standard errors. The percentage change in coronary artery diameter in response to acetylcholine, as a metric of epicardial endothelial function, was similar between patients with hypothyroidism and euthyroidism among all patients and after stratifying by sex. % Δ CAD Ach indicates percentage change in coronary artery diameter in response to acetylcholine; % Δ CBF Ach, percentage change in coronary blood flow in response to acetylcholine.](jah30004-e002225-f2){#fig02}

![A, Multivariable adjusted average maximum-percentage change in coronary blood flow in response to acetylcholine in patients with hypothyroidism compared to euthyroidism. \*Signifies *P*\<0.05; T-bars represent standard errors. In males, estimates were adjusted for age, hypertension, diabetes mellitus, body mass index, and total and high-density lipoprotein-cholesterol. In females, estimates were adjusted for age, hypertension, diabetes mellitus, body mass index, and total and high-density lipoprotein-cholesterol and the use of estrogen replacement therapy. Females with hypothyroidism had a significantly lower percentage change in coronary blood flow in response to acetylcholine, a metric of microvascular endothelial function, compared to patients with euthyroidism even after adjusting for potential confounders. B, Multivariable adjusted average maximum-percentage change in coronary artery diameter in response to acetylcholine in patients with hypothyroidism compared to euthyroidism. T-bars represent standard errors. In males, estimates were adjusted for age, hypertension, diabetes mellitus, body mass index, and total and high-density lipoprotein-cholesterol. In females, estimates were adjusted for age, hypertension, diabetes mellitus, body mass index, and total and high-density lipoprotein-cholesterol and the use of estrogen replacement therapy. Patients with hypothyroidism had a similar percentage change in coronary artery diameter in response to acetylcholine, a metric of epicardial endothelial function, compared to patients with euthyroidism, even after stratifying by sex and adjusting for potential confounders. % Δ CAD Ach indicates percentage change in coronary artery diameter in response to acetylcholine; % Δ CBF Ach, percentage change in coronary blood flow in response to acetylcholine.](jah30004-e002225-f3){#fig03}

Among males, there was no significant difference in the % Δ CBF Ach or % Δ CAD Ach in the univariate analysis ([Figure 2A](#fig02){ref-type="fig"} and [2B](#fig02){ref-type="fig"}) or after adjusting for potential confounders ([Figure 3A](#fig03){ref-type="fig"} and [3B](#fig03){ref-type="fig"}). However, among females, the hypothyroid group had a significantly lower % Δ CBF Ach (mean \[SD\] %: 46.34 \[79.85\] versus 65.28 \[101.89\], *P*\<0.05) compared to the euthyroid group ([Figure 2A](#fig02){ref-type="fig"}), but the % Δ CAD Ach did not vary significantly between groups ([Figure 2B](#fig02){ref-type="fig"}). When adjusting for diabetes, hypertension, age, BMI, total and HDL cholesterol, and the use of estrogen replacement therapy, hypothyroidism remained significantly associated with % Δ CBF Ach (estimate \[SE\] %: −16.79 \[8.18\], *P*\<0.05) ([Figure 3A](#fig03){ref-type="fig"}) but not % Δ CAD Ach ([Figure 3B](#fig03){ref-type="fig"}), implying that females with hypothyroidism had worse microvascular endothelial function compared to females with euthyroidism, even after adjusting for covariates.

Adequate Replacement on TRT and Coronary Endothelial Function
-------------------------------------------------------------

Of the 188 patients with a history of hypothyroidism or TSH \>10 mU/L, 184 were prescribed TRT at the time of the index procedure. Twenty-five of these patients did not have a TSH level documented within 1 month of the index procedure and were excluded, leaving 159 patients for this subanalysis ([Figure 1](#fig01){ref-type="fig"}). One hundred forty-nine patients (94%) with hypothyroidism had adequate replacement on TRT, defined as 0.3\<TSH≤10.0 mU/mL, and 10 had inadequate replacement (TSH \>10.0 mU/mL).[@b44] There were no significant differences in the % Δ CAD Ach and % Δ CBF Ach between groups ([Table 2](#tbl2){ref-type="table"}). In a multivariate analysis adjusting for age, sex, diabetes, hypertension, BMI, and total and HDL cholesterol, adequate replacement on TRT was not significantly associated with the % Δ CAD Ach or % Δ CBF Ach ([Table 3](#tbl3){ref-type="table"}).

###### 

Average Maximum % Δ CAD Ach and % Δ CBF Ach in Hypothyroid Patients Taking Thyroid Replacement Therapy With Adequate Versus Inadequate Replacement

  All Subjects   Adequate Replacement N=149   Inadequate Replacement N=10   *P* Value
  -------------- ---------------------------- ----------------------------- -----------
  \% Δ CAD Ach   −8.58 (−22.47, 0.24)         −9.76 (−20.71, 1.58)          0.88
  \% Δ CBF Ach   29.61 (−11.74, 106.92)       −7.27 (−24.56, 178.59)        0.60

\% Δ CAD Ach indicates percentage change in coronary artery diameter in response to acetylcholine; % Δ CBF Ach, percentage change in coronary blood flow in response to acetylcholine.

###### 

Multivariate Analysis of the Association Between Adequate Replacement on TRT and Average Maximum % Δ CAD Ach and % Δ CBF in Subjects With Hypothyroidism

  All Subjects[\*](#tf3-2){ref-type="table-fn"}    \% Δ CAD Ach   *P* Value   \% Δ CBF Ach    *P* Value
  ------------------------------------------------ -------------- ----------- --------------- -----------
  Inadequate vs adequate replacement on TRT (SD)   −1.02 (3.48)   0.77        −6.31 (15.72)   0.69

\% Δ CAD Ach indicates percentage change in coronary artery diameter in response to acetylcholine; % Δ CBF Ach, percentage change in coronary blood flow in response to acetylcholine; TRT, thyroid replacement therapy.

Adjusted for age, sex, body mass index, hypertension, diabetes mellitus, and total and high-density lipoprotein-cholesterol.

Thyroid-stimulating hormone as a Biomarker of Coronary Endothelial Function
---------------------------------------------------------------------------

Among the 1439 patients with measurements available for both % Δ CBF Ach and % Δ CAD Ach, 1175 had TSH levels documented within 1 month of the index procedure, of which 27 were excluded due to a TSH \<0.3 mU/mL, leaving 1148 patients for this analysis ([Figure 1](#fig01){ref-type="fig"}). TSH did not correlate significantly with either the % Δ CAD Ach (*r*=0.028, 95% CI −0.030 to 0.086) or the % Δ CBF Ach (*r*=0.011 95% CI −0.047 to 0.069). Patients were divided into 3 groups according to their TSH level: euthyroid, 0.3\<TSH≤4.5 mU/mL, n=1050; SCH, 4.5\<TSH≤10.0 mU/mL, n=86 and hypothyroid, TSH \>10 mU/mL, n=12. There were no significant differences in the % Δ CBF Ach or the % Δ CAD Ach ([Table 4](#tbl4){ref-type="table"}). After adjusting for age, sex, diabetes, hypertension, BMI, and total and HDL cholesterol, neither hypothyroidism nor SCH were significantly associated with % Δ CBF Ach or % Δ CAD Ach (data not shown).

###### 

Average Maximum % Δ CAD Ach and Average Maximum % Δ CBF Ach Between Subjects Divided According to Serum TSH Levels

                 TSH 0.3 to 4.5 mU/mL N=1050   TSH 4.5 to 10 mU/mL N=86   TSH \>10 mU/mL N=12      *P* Value
  -------------- ----------------------------- -------------------------- ------------------------ ------------------------------------------
  TSH, mU/mL     1.80 (1.20, 2.70)             5.75 (5.00, 6.80)          17.05 (12.75, 24.63)     \<0.001[\*](#tf4-3){ref-type="table-fn"}
  \% Δ CAD Ach   −10.58 (−25.42, 0.00)         −7.70 (−22.19, 00)         −6.15 (−16.16, 1.67)     0.26
  \% Δ CBF Ach   40.28 (−7.45, 100.41)         68.52 (6.28, 121.98)       22.19 (−21.84, 189.20)   0.16

Values in parenthesis are quartiles 1 and quartiles 3; median (Q1,Q3).

\% Δ CAD Ach indicates percentage change in coronary artery diameter in response to acetylcholine; % Δ CBF Ach, percentage change in coronary blood flow in response to acetylcholine; TSH, thyroid-stimulating hormone.

signifies *P*\<0.05

Discussion
==========

Hypothyroidism Is Associated With Endothelial Dysfunction in Women
------------------------------------------------------------------

In the current study, we show that while the % Δ CAD Ach (an index of epicardial endothelial function) was not significantly different between patients with and without hypothyroidism, the % Δ CBF Ach (an index for microvascular endothelial function) was lower in patients with hypothyroidism, and remained lower in females after stratifying by sex. In fact, the % Δ CBF Ach in all patients and among females was \<50%, a previously used threshold to identify microvascular endothelial dysfunction.[@b21],[@b41],[@b45] While some of this may be explained by the concurrent association between hypothyroidism and endothelial dysfunction with conventional cardiovascular risk factors, females with hypothyroidism still had an impaired % Δ CBF ACh after adjusting for these variables. Thus, the current study suggests an independent link between hypothyroidism and the regulation of endothelial function.

By showing that hypothyroidism is associated with coronary endothelial dysfunction, our findings are consistent with the results of previous studies ([Table 5](#tbl5){ref-type="table"}) in which microvascular endothelial function was evaluated in the brachial artery using noninvasive measurements of forearm blood flow.[@b36],[@b38] However, the current study did not show a significant difference in epicardial (macrovascular) endothelial function between patients with hypothyroidism and euthyroidism. While some studies evaluating macrovascular endothelial function in the brachial artery showed that patients with hypothyroidism had lower flow-mediated dilatation compared to those with euthyroidism,[@b32],[@b33],[@b37] this remains controversial as other studies have failed to show a difference between groups.[@b35] The current study extends the observations of these previous studies into the coronary circulation and sheds new light onto the potential association between hypothyroidism and endothelial function by using invasive techniques to directly quantify % Δ CBF Ach and % Δ CAD Ach in, to our knowledge, the largest published cohort of hypothyroid patients evaluated for endothelial dysfunction. Moreover, dissociation between epicardial and microvascular endothelial function has been previously identified.[@b46] For example, smokers without evidence of significant CAD have abnormal epicardial endothelial function and preserved microvascular endothelial function.[@b47] Thus, there may be a different susceptibility of the microvascular and epicardial circulation to the effects of risk factors. Evidently, hypothyroidism preferentially affects the microvascular system, although it might subsequently progress to impair epicardial function. As to why various risk factors and specifically hypothyroidism have a predilection for the microvascular system compared to the epicardial system needs to be clarified.

###### 

Summary of Previous Studies Evaluating the Relationship Between Hypothyroidism and Endothelial Dysfunction

  Study                     Study Design      Sample Size                         Investigating Technique                                       Conclusion
  ------------------------- ----------------- ----------------------------------- ------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
  Lekakis et al[@b32]       Cross-sectional   35 (mean age51.0 y, 94% female)     FMD of brachial artery using arm cuff and USS                 FMD is lower in patients with hypothyroidism
  Papaioannou et al[@b33]   Prospective       8 (mean age 48.9 y, 38% female)     FMD of brachial artery using arm cuff and USS                 TRT improves FMD in patients with hypothyroidism
  Biondi et al[@b34]        Cross-sectional   35 (mean age 34.8 y, 100% female)   CFR of LAD using transthoracic echo                           CFR is lower in patients with SCH
  Cabral et al[@b35]        Cross-sectional   42 (mean age 42.4 y, 100% female)   FMD of brachial artery using arm cuff and USS                 FMD is *not* lower in patients with hypothyroidism
  Dagre et al[@b36]         Cross-sectional   96 (mean age 42.0 y, 100% female)   FMD of brachial artery using arm cuff and USS                 FBF is lower in patients with hypothyroidism At least 3 mo of well-controlled hypothyroidism on TRT improves FBF
  Shavdatuashvili[@b37]     Cross-sectional   70 (age unknown, 100% female)       FMD of brachial artery using arm cuff and USS                 FMD is lower in patients with hypothyroidism
  Erbil et al[@b38]         Prospective       44 (mean age 46.9 y, 91% female)    FMD of brachial artery using arm cuff and USS                 FMD is lower in patients with hypothyroidism FMD improves after 6 mo of TRT in patients with hypothyroidism
  Razvi et al[@b39]         Prospective       100 (mean age 53.8 y, 81% female)   FMD of brachial artery using arm cuff and USS                 At least 12 wks of TRT improves FMD in patients with SCH
  Taddei et al[@b40]        Cross-sectional   42 (demographics not stated)        FMD of brachial artery using acetylcholine infusion and USS   FBF is lower in patients with hypothyroidism At least 6 mo of TRT improves FBF in patients with hypothyroidism

CFR indicates coronary flow reserve, FBF, forearm blood blow; FMD, forearm-mediated dilatation; LAD, Left Anterior Descending coronary artery; SCH, subclinical hypothyroidism; TRT, thyroid replacement therapy; USS, ultrasound scan.

After adjusting for confounders, we showed that hypothyroidism was associated with microvascular endothelial dysfunction in females. Indeed, women receiving treatment for hypothyroidism require higher doses of TRT in pregnancy[@b48] and during exogenous estrogen therapy.[@b49] Estrogen is believed to increase concentrations of thyroid-binding globulin, which binds thyroxine and in turn reduces levels of free thyroxine, limiting its effects on tissues. In contrast, androgens such as testosterone reduce the synthesis of thyroid-binding globulin, resulting in transiently increased levels of free thyroxine. Interestingly, androgen administration in hypothyroid women was shown to cause clinical manifestations of hyperthyroidism.[@b50] Thus, baseline differences in hormone profile and the subsequent transient effects on free thyroxine levels may render females more vulnerable to the effects of thyroid status. This is further supported by the results of a community health survey in which serum TSH levels correlated with serum total cholesterol, low-density lipoprotein-cholesterol, and triglycerides levels more strongly in females compared with males.[@b51]

Clinical Profile of Hypothyroidism
----------------------------------

Hypothyroidism is associated with accelerated atherosclerosis and an increased risk of CAD.[@b1]--[@b3] A significant proportion of this can be explained by the independent association between hypothyroidism and conventional cardiovascular risk factors.[@b4]--[@b7],[@b52]--[@b54] Our findings support these associations, as hypothyroid patients in this study were significantly older, had a higher BMI, a higher prevalence of diabetes, and a higher total cholesterol level compared to the euthyroid group. Nevertheless, not all individuals with hypothyroidism have conventional risk factors,[@b8] suggesting that other factors may be implicated in their increased risk. This is further supported by studies that have shown an increased risk of all-cause mortality[@b9] and cardiovascular events[@b10] in hypothyroid patients, even after adjusting for conventional risk factors. Coronary endothelial dysfunction may account for some of the increased risk in hypothyroid patients as it is an independent risk factor for atherosclerosis and cardiovascular events.[@b26],[@b27]

The precise mechanisms by which hypothyroidism affects endothelial function are not entirely clear. Isoforms of the thyroid hormone receptor have been identified in human aortic vascular smooth muscle cells,[@b55] suggesting that thyroid hormone may act directly on the vascular bed and influence vasomotion. Other studies have correlated hypothyroidism with the presence of anti--endothelial cell antibodies,[@b56] which may be related to its autoimmune etiology in many patients. Endothelial dysfunction has also been linked to elevated local coronary[@b29] and systemic[@b30] levels of biomarkers such as lipoprotein-lipase A2 as well as the local presence of macrophages and microchannels, features consistent with inflammation.[@b28] Previous studies have also shown that hypothyroidism is also associated with low-grade systemic inflammation, which may act as the potential trigger leading to endothelial dysfunction.[@b57] However, the precise mechanisms involved require clarification.

Treating Hypothyroidism
-----------------------

In the current study, we did not observe that adequate replacement with TRT in hypothyroid patients was associated with better epicardial or microvascular endothelial function, even after adjusting for potential confounders. Other studies have shown an improvement in noninvasively measured flow-mediated dilatation in hypothyroid patients treated with thyroxine.[@b33],[@b39],[@b40] In 2 of these studies, the sample size was very small (14 and 8 patients, respectively) while in the third, the observed difference in flow-mediated dilatation of 1.7% may not be clinically relevant. In an additional study, flow-mediated dilatation did not improve in hypothyroid patients until at least 6 months of treatment with TRT.[@b38] Thus, the duration of treatment with TRT may be important, and while using TRT in hypothyroidism has been shown to result in favorable changes to cardiovascular risk factors,[@b58] its precise role in modifying endothelial dysfunction requires further study. Thus, the current study supports the need for developing novel treatments for endothelial dysfunction directed at specific therapeutic targets.

Thyroid-stimulating hormone as a Biomarker
------------------------------------------

The current study demonstrated that TSH levels drawn within 1 month of the index procedure did not correlate significantly with the % Δ CBF Ach or the % Δ CAD Ach. In addition, when using TSH alone to categorize patients as euthyroid, SCH, or hypothyroid, no significant differences were observed in endothelial function in either microvascular or epicardial vessels. This may be a reflection of the fact that SCH has often not been shown to be a clinically important risk factor for cardiovascular disease.[@b59],[@b60] Nevertheless, the current study does not support the use of TSH as a biomarker to identify patients likely to have coronary endothelial dysfunction. This is in keeping with the consensus opinion that the routine screening of asymptomatic adults for thyroid dysfunction using TSH as a means of risk preventative health care is not recommended.[@b60]

Study Limitations
-----------------

This study is limited by its retrospective and cross-sectional design. We were therefore unable to establish a causal relationship between hypothyroidism and endothelial dysfunction. Second, we did not prospectively follow patients with epicardial or microvascular coronary endothelial dysfunction for clinical events and so cannot comment on the clinical significance of these abnormalities. Third, we did not follow hypothyroid patients taking TRT to ascertain temporal changes in % Δ CBF Ach or % Δ CAD Ach. Fourth, some of our analyses may be limited by a small sample size. For example, the lack of finding a significant adjusted association between hypothyroidism and coronary endothelial dysfunction in the subset of men may be due to the small number of men with hypothyroidism included in the study. Similarly, the small number of hypothyroid patients with inadequate replacement on thyroid replacement therapy, as well as the small number of patients with TSH 4.5 to 10.0 mU/mL and TSH \>10.0 mU/mL, may limit each of these analyses. Lastly, the current study is based on patients who were referred for coronary angiography to a tertiary referral center by an independent cardiologist and so constitute a unique population.

Conclusions
===========

Hypothyroidism in women referred for coronary angiography is associated with microvascular endothelial dysfunction, even after adjusting for potential confounders, and may explain some of the increased risk of atherosclerotic cardiovascular disease in these patients. Adequate replacement with TRT in patients with hypothyroidism is not associated with better endothelial function, underscoring the need to develop novel therapies targeted at endothelial dysfunction.
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